Mak Capital One LLC Takes Position in CryoPort, Inc. $CYRX

Mak Capital One LLC purchased a new position in shares of CryoPort, Inc. (NASDAQ:CYRX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 818,162 shares of the company’s stock, valued at approximately $7,756,000. CryoPort accounts for 1.2% of Mak Capital One LLC’s investment portfolio, making the stock its 11th largest holding.

A number of other institutional investors and hedge funds have also bought and sold shares of CYRX. Vanguard Group Inc. raised its position in CryoPort by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,858,031 shares of the company’s stock worth $27,094,000 after purchasing an additional 69,550 shares during the last quarter. Millennium Management LLC lifted its holdings in CryoPort by 18.5% during the 3rd quarter. Millennium Management LLC now owns 2,620,906 shares of the company’s stock worth $24,846,000 after buying an additional 408,335 shares during the period. Thematics Asset Management grew its position in shares of CryoPort by 12.8% in the 2nd quarter. Thematics Asset Management now owns 1,914,885 shares of the company’s stock valued at $14,285,000 after buying an additional 216,937 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of CryoPort by 37.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company’s stock valued at $14,208,000 after buying an additional 408,263 shares during the last quarter. Finally, UBS Group AG increased its stake in shares of CryoPort by 112.7% in the third quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock valued at $12,623,000 after buying an additional 705,649 shares during the period. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CYRX has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a research report on Monday, December 29th. Needham & Company LLC increased their target price on shares of CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Finally, Wall Street Zen lowered shares of CryoPort from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, CryoPort currently has a consensus rating of “Moderate Buy” and an average target price of $12.94.

CryoPort Price Performance

Shares of NASDAQ:CYRX opened at $8.00 on Tuesday. The company has a market capitalization of $398.88 million, a price-to-earnings ratio of 6.06 and a beta of 1.69. The business’s 50-day moving average is $9.23 and its 200-day moving average is $9.36. CryoPort, Inc. has a 1 year low of $4.63 and a 1 year high of $11.45.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The business had revenue of $45.45 million for the quarter, compared to the consensus estimate of $42.92 million. CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%. Analysts anticipate that CryoPort, Inc. will post -0.99 EPS for the current year.

Insider Transactions at CryoPort

In other CryoPort news, CFO Robert Stefanovich sold 38,700 shares of the firm’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $7.76, for a total value of $300,312.00. Following the completion of the sale, the chief financial officer directly owned 255,701 shares in the company, valued at approximately $1,984,239.76. This trade represents a 13.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 10.10% of the stock is currently owned by corporate insiders.

CryoPort Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.